A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate
  • Indications Juvenile rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 09 Sep 2009 Additional trial location (Czech Republic) identified as reported by ClinicalTrials.gov.
    • 29 Oct 2008 3-year results presented at ACR/ARHP 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top